P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma

Takeshi Terashima, Eishiro Mizukoshi, Kuniaki Arai, Tatsuya Yamashita, Mariko Yoshida, Hajime Ota, Ichiro Onishi, Masato Kayahara, Koushiro Ohtsubo, Takashi Kagaya, Masao Honda, Shuichi Kaneko
  • Cancer Immunology Immunotherapy, March 2014, Springer Science + Business Media
  • DOI: 10.1007/s00262-014-1529-8

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1007/s00262-014-1529-8

The following have contributed to this page: Takeshi Terashima

In partnership with:

Contributors